GlobeNewsWire
30 Jun 2026, 23:32 UTC · 2h ago
Aptose Biosciences Announces Completion of Acquisition by Hanmi Pharmaceutical
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
GlobeNewsWire
30 Jun 2026, 23:32 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Hanmi Pharmaceutical has completed the acquisition of all outstanding common shares of Aptose Biosciences. — The completion of a buyout removes the company from the public market and provides immediate liquidity to shareholders.
+0.50Aptose shareholders will receive C$2.41 in cash per share, representing a 28% premium over the 30-day VWAP of C$1.88. — The premium confirms the valuation floor and provides a positive realized return for remaining shareholders.
+0.40Aptose common shares are expected to be delisted from the Toronto Stock Exchange on or about July 3, 2026. — Delisting is the final mechanical step of the acquisition, ending the tradability of the stock.
+0.20Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
The company was acquired at a 28% premium over its 30-day VWAP.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
5h ago
